Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects

Biomarker Research

Review

Pablo Cano-Ramírez¹  María Victoria García-Ortiz²  Marta Toledano-Fonseca²  Antonio Rodríguez-Ariza³  Enrique Aranda⁴ 

[1] Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain;Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology, Sevilla, Spain;Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain;Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology, Sevilla, Spain;Cancer Network Biomedical Research Center (CIBERONC), Madrid, Spain;Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain;Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology, Sevilla, Spain;Cancer Network Biomedical Research Center (CIBERONC), Madrid, Spain;Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain;Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain;Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology, Sevilla, Spain;Cancer Network Biomedical Research Center (CIBERONC), Madrid, Spain;Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain;Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba, Spain;

关键词: Biomarkers;    Cell-free DNA;    Epigenetics;    Liquid biopsy;    Methylation;    Pancreatic cancer;   

DOI  :  10.1186/s40364-023-00528-y

 received in 2023-07-24, accepted in 2023-09-21,  发布年份 2023

来源: Springer

【 摘 要 】

Pancreatic cancer is one of the most challenging cancers due to its high mortality rates. Considering the late diagnosis and the limited survival benefit with current treatment options, it becomes imperative to optimize early detection, prognosis and prediction of treatment response. To address these challenges, significant research efforts have been undertaken in recent years to develop liquid-biopsy-based biomarkers for pancreatic cancer. In particular, an increasing number of studies point to cell-free DNA (cfDNA) methylation analysis as a promising non-invasive approach for the discovery and validation of epigenetic biomarkers with diagnostic or prognostic potential. In this review we provide an update on recent advancements in the field of cfDNA methylation analysis in pancreatic cancer. We discuss the relevance of DNA methylation in the context of pancreatic cancer, recent cfDNA methylation research, its clinical utility, and future directions for integrating cfDNA methylation analysis into routine clinical practice.

【 授权许可】

CC BY   
© Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 2